pirfenidone has been researched along with galactosamine in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cain, WC; Lefkowitz, DL; Lefkowitz, SS; Margolin, S; Starnes, JD; Stuart, RW | 1 |
| Horikawa, T; Nakazato, H; Oku, H; Suzuki, R; Tsuruta, Y | 1 |
| Chen, XY; Wang, F; Wen, T; Wu, H | 1 |
3 other study(ies) available for pirfenidone and galactosamine
| Article | Year |
|---|---|
Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Immunologic; Galactosamine; Injections, Intraperitoneal; Interleukin-6; Lipopolysaccharides; Macrophages, Peritoneal; Male; Mice; Mice, Inbred C57BL; Pyridones; Shock, Septic; Thioglycolates; Tumor Necrosis Factor-alpha | 1998 |
Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Galactosamine; Interferon-gamma; Interleukin-10; Interleukin-12; Lipopolysaccharides; Liver; Liver Failure; Mice; Mice, Inbred C57BL; Necrosis; Pyridones; Shock, Septic; Transforming Growth Factor beta; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha | 2002 |
Protective effects of pirfenidone on D-galactosamine and lipopolysaccharide-induced acute hepatotoxicity in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Chemical and Drug Induced Liver Injury; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Galactosamine; Inflammation; Lipid Peroxidation; Lipopolysaccharides; Liver; Liver Diseases; Male; Nitric Oxide; Nitric Oxide Synthase Type II; Pyridones; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2008 |